{"title":"Dendritic cell therapy for oncology roundtable conference.","authors":"Sandra Tuyaerts","doi":"10.1186/1476-8518-9-1","DOIUrl":null,"url":null,"abstract":"<p><p> 2-3 September 2010, Brussels, BelgiumThe Dendritic Cell Therapy for Oncology Roundtable Conference was organized by Reliable Cancer Therapies and moderated by Prof. Dr. Steven De Vleeschouwer. The organizer, Reliable Cancer Therapies, is a Swiss non-profit organization that provides information on evidence-based cancer treatments and funding for the development of a selection of promising cancer therapies. In order to be able to give valuable information about dendritic cell (DC) therapy to patients and physicians, the organizing committee felt it necessary to organize this conference to get an up-to-date status of the academic DC therapy field, collect ideas to guide patients towards clinical trials and to induce cross-fertilization for protocol optimization. In total, 31 experts participated to an in-depth discussion about the status and the future development path for dendritic cell vaccines. The conference started with general presentations about cancer immunotherapy, followed by comprehensive overview presentations about the progress in DC vaccine development achieved by each speaker. At the end of the meeting, a thorough general discussion focused on key questions about what is needed to improve DC vaccines. This report does not cover all presentations, but aims to highlight selected points of interest, particularly relating to possible limitations and potential approaches to improvement of DC therapies specifically, and also immunotherapeutic interventions in general terms.</p>","PeriodicalId":84998,"journal":{"name":"Journal of immune based therapies and vaccines","volume":"9 1","pages":"1"},"PeriodicalIF":0.0000,"publicationDate":"2011-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1476-8518-9-1","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of immune based therapies and vaccines","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/1476-8518-9-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 11
Abstract
2-3 September 2010, Brussels, BelgiumThe Dendritic Cell Therapy for Oncology Roundtable Conference was organized by Reliable Cancer Therapies and moderated by Prof. Dr. Steven De Vleeschouwer. The organizer, Reliable Cancer Therapies, is a Swiss non-profit organization that provides information on evidence-based cancer treatments and funding for the development of a selection of promising cancer therapies. In order to be able to give valuable information about dendritic cell (DC) therapy to patients and physicians, the organizing committee felt it necessary to organize this conference to get an up-to-date status of the academic DC therapy field, collect ideas to guide patients towards clinical trials and to induce cross-fertilization for protocol optimization. In total, 31 experts participated to an in-depth discussion about the status and the future development path for dendritic cell vaccines. The conference started with general presentations about cancer immunotherapy, followed by comprehensive overview presentations about the progress in DC vaccine development achieved by each speaker. At the end of the meeting, a thorough general discussion focused on key questions about what is needed to improve DC vaccines. This report does not cover all presentations, but aims to highlight selected points of interest, particularly relating to possible limitations and potential approaches to improvement of DC therapies specifically, and also immunotherapeutic interventions in general terms.
2010年9月2-3日,比利时布鲁塞尔,树突状细胞肿瘤治疗圆桌会议由可靠癌症治疗组织,Steven De Vleeschouwer教授主持。该活动的组织者,可靠的癌症治疗,是一个瑞士的非营利组织,提供基于证据的癌症治疗信息,并为有前途的癌症治疗的发展提供资金。为了能够向患者和医生提供有关树突状细胞(DC)治疗的有价值的信息,组委会认为有必要组织这次会议,以了解树突状细胞治疗领域的最新学术状况,收集指导患者进行临床试验的想法,并诱导交叉受精以优化方案。共有31名专家参加了关于树突状细胞疫苗的现状和未来发展路径的深入讨论。会议以癌症免疫治疗的一般介绍开始,随后由每位演讲者对DC疫苗开发进展进行全面概述。在会议结束时,进行了全面的一般性讨论,重点讨论了改进DC疫苗所需的关键问题。本报告不包括所有的报告,但旨在强调选定的兴趣点,特别是与可能的局限性和潜在的方法有关,特别是改善DC治疗,以及一般的免疫治疗干预。